Antibodies as Drugs: Translating Molecules into Treatments
Organizer(s): Paul W. H. I. Parren and Erica Ollmann SaphireDate: February 25 - March 01, 2018
Location: Whistler Conference Centre, Whistler, BC, Canada
Antibodies carry an enormous potential in prophylaxis and treatment of human disease. Antibody therapies may be divided into two distinct but highly related disciplines. First, antibodies can be elicited de novo using vaccines. Our understanding of what constitutes an effective antibody response at the molecular level and the science of eliciting such antibodies in vivo are progressing rapidly. Secondly, isolated antibodies represent powerful drugs when developed as biopharmaceuticals, as demonstrated by the ever-expanding list of approved molecules as well as by the large number of antibody products in development in a wide range of therapeutic areas. The antibody landscape is changing as the field has moved from empirical to knowledge-based, designer approaches for which understanding of mechanisms of action at the molecular level is critical. Translating such basic knowledge into novel products and applications requires scientists from many disciplines including structural and cellular immunology, biology, engineering, chemistry and medicine to interact closely. Consequently, the field of antibody-based vaccines and therapeutics has become an interface area where experts meet and work together. The 2018 Keystone Symposia antibodies conference aims to provide a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases.
Scholarship Deadline: October 24 2017
Discounted Abstract Deadline: October 24 2017
Abstract Deadline: November 21 2017
Discounted Registration Deadline: December 19 2017
We gratefully acknowledge additional support for this conference from:
Berkeley Lights, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
EMBO Young Investigator Programme
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 R13 AI136247-01
Funding for this conference was made possible (in part) by 1 R13 AI136247-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.